Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00068211 · ClinicalTrials.gov registry record · Phase 2
Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma
A Phase 2 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00068211 is a Phase 2 study that has completed, run by Genzyme, a Sanofi Company.
The verdict
NCT00068211, a Phase 2 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
This is a Phase II, non-randomized, open label study of ILX651 in patients with inoperable locally advanced or metastatic melanoma. Approximately 60 patients will be enrolled in this study that is expected to last 18 months. All patients will be treated with ILX651 administered IV daily for 5 consecutive days once every 21 days. The primary objective of this study is to determine the overall response rate for all patients who are treated with ILX651. The secondary objectives are to determine the progression free survival at 18 weeks, duration of response, time to tumor progression, survival, safety/tolerability of ILX651 and to evaluate the pharmacokinetic profile.
Interventions
- DRUG ILX651
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-08 |
| Est. Completion | 2006-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00068211
The ClinicalTrials.gov registry entry for NCT00068211 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ILX651 is the first listed.
NCT00068211 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00068211 about?
NCT00068211 is a clinical study titled "Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma". This is a Phase II, non-randomized, open label study of ILX651 in patients with inoperable locally advanced or metastatic melanoma. Approximately 60 patients will be enrolled in this study that is expected to last 18 months. All patients will be treated with ILX651 administered IV daily for 5 consec...
What is the current status of trial NCT00068211?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-08. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00068211?
The interventions under investigation include: ILX651 (DRUG).
Who is sponsoring clinical trial NCT00068211?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.